Zheng M, Luo J, Chen Z
Shanghai Institute of Biological Products, Shanghai, 200052, China.
Infection. 2014 Apr;42(2):251-62. doi: 10.1007/s15010-013-0546-4. Epub 2013 Nov 1.
Vaccination is the safest and most effective measure against influenza virus infections. However, traditional influenza vaccines cannot respond effectively to an unforeseen epidemic or pandemic caused by a virus with antigenic drifts or antigenic shifts. Therefore, developing a universal influenza vaccine (UIV) that induces broad-spectrum and long-term immunity has become a major trend in influenza vaccine research and development.
This article reviews the development of UIVs based on these conserved influenza virus proteins.
The matrix protein (M1, M2) and nucleoprotein (NP) of influenza viruses have highly conserved sequences, and they become the major target antigens of current UIV studies.
接种疫苗是预防流感病毒感染最安全、最有效的措施。然而，传统流感疫苗无法有效应对由抗原漂移或抗原转变的病毒引发的意外流行或大流行。因此，研发一种能诱导广谱和长期免疫的通用流感疫苗（UIV）已成为流感疫苗研发的主要趋势。
本文综述了基于这些保守流感病毒蛋白的通用流感疫苗的研发情况。
流感病毒的基质蛋白（M1、M2）和核蛋白（NP）具有高度保守的序列，它们成为当前通用流感疫苗研究的主要靶抗原。
